13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001816307
Total reported value
$962.2M
$962.2M
69 檔
14.1%
During the Q3 2024 filing period, Silverarc Capital Management, LLC (CIK: 0001816307) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $962.2M across 69 reported positions.
During Q3 2024, Silverarc Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including NUVL, MERUS N V, INSM) accounted for 14.1% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc-a | Stock-Other | 8.53% | -3.71% | EXIT | |
| 2 | ✓ | Merus N V | Stock-Other | 7.13% | — | +1.89% | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 5.70% | -0.22% | +148.35% | |
| 4 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 4.91% | — | -8.15% | |
| 5 | ERAS | Erasca Inc | Stock-Other | 4.26% | -0.66% | -11.14% | |
| 6 | AKRO | Akero Therapeutics Inc | Stock-Other | 4.12% | — | +2.36% | |
| 7 | VCYT | Veracyte Inc | Stock-Other | 3.60% | +1.35% | +66.72% | |
| 8 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.01% | +0.87% | +38.40% | |
| 9 | COGT | Cogent Biosciences Inc | Stock-Other | 2.96% | -0.01% | +1.26% | |
| 10 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.75% | — | -13.12% | |
| 11 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.67% | -1.89% | EXIT | |
| 12 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.57% | +2.22% | -18.23% | |
| 13 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.53% | -0.59% | +2.20% | |
| 14 | PSTXUSD | Poseida Therapeutics Inc | Stock-Other | 2.37% | — | +2.20% | |
| 15 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.25% | — | +14.52% | |
| 16 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.21% | — | -0.63% | |
| 17 | GERN | Geron CORP | Stock-Other | 1.84% | — | +80.29% | |
| 18 | CCCC | C4 Therapeutics Inc | Stock-Other | 1.66% | +0.96% | -10.05% | |
| 19 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.64% | +0.64% | +2.36% | |
| 20 | PCVX | Vaxcyte Inc | Stock-Other | 1.55% | +0.02% | +2320.00% | |
| 21 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.49% | -5.91% | EXIT | |
| 22 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.48% | — | — | |
| 23 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.44% | — | +22.01% | |
| 24 | ✓ | Biodesix Inc | Stock-Other | 1.42% | — | +96.86% | |
| 25 | ELUT | Elutia Inc | Stock-Other | 1.41% | -0.05% | +2.63% | |
| 26 | ✓ | Adc Therapeutics SA | Stock-Other | 1.27% | — | +1.49% | |
| 27 | GOSS | Gossamer Bio Inc | Stock-Other | 1.25% | — | +2.64% | |
| 28 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.22% | — | -16.78% | |
| 29 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.20% | — | +2.67% | |
| 30 | ABVX | Abivax Sa-adr | Stock-Other | 1.19% | -1.09% | +1.29% | |
| 31 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.16% | — | +26.66% | |
| 32 | IRON | Disc Medicine Inc | Stock-Other | 1.15% | -0.65% | +2.64% | |
| 33 | BHVN | Biohaven Ltd. | Stock-Other | 1.12% | — | -0.43% | |
| 34 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.11% | -0.58% | EXIT | |
| 35 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 0.93% | — | +1.22% | |
| 36 | BIIB | Biogen Inc | Stock-Healthcare | 0.87% | +0.13% | +2.97% | |
| 37 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.87% | -0.06% | -0.37% | |
| 38 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.74% | — | -29.85% | |
| 39 | ✓ | Modular Med Inc | Stock-Other | 0.73% | — | +60.00% | |
| 40 | SLDB | Solid Biosciences Inc | Stock-Other | 0.72% | +0.69% | NEW | |
| 41 | BNTX | Biontech Se-adr | Stock-Other | 0.70% | — | — | |
| 42 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 43 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.67% | — | — | |
| 44 | TELA | Tela Bio Inc | Stock-Other | 0.64% | +0.03% | +12.49% | |
| 45 | ✓ | Compugen LTD | Stock-Other | 0.61% | -0.01% | — | |
| 46 | CERS | Cerus CORP | Stock-Other | 0.58% | +0.46% | +2.02% | |
| 47 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 0.55% | — | — | |
| 48 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.50% | — | -35.39% | |
| 49 | BIOA | Bioage Labs Inc | Stock-Other | 0.47% | — | — | |
| 50 | ✓ | Stock-Other | 0.37% | — | — |
According to official SEC Form 13F filings, Silverarc Capital Management, LLC reported a total U.S. public equity portfolio value of $962.2M across 69 disclosed positions in Q3 2024.
During Q3 2024, Silverarc Capital Management, LLC's top holdings by market value included NUVL (8.5%)、MERUS N V (7.1%)、INSM (5.7%). The largest single position, NUVL, represented 8.5% of total portfolio value.
In Q3 2024, Silverarc Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.